Tyler Menichiello
Tyler Menichiello is a contributing editor to Bioprocess Online, Cell & Gene, and Clinical Leader. He interviews executives and subject matter experts across the biopharma industry to write about their successful approaches in biologics development from pre-IND planning all the way through trial design, manufacturing, and commercialization. He aims to investigate the industry’s most prevalent challenges and emerging best practices to provide both interesting and actionable content for industry leaders. Prior to writing for Life Science Connect, Tyler spent two years as a clinical research associate at the University of Pittsburgh Medical Center’s (UPMC) Hillman Cancer Center, where he worked on clinical trials involving hematological malignancies. He studied biology and journalism at Indiana University of Pennsylvania (IUP). You can email Tyler at tyler.menichiello@lifescienceconnect.com, or visit his LinkedIn profile.
ARTICLES BY TYLER MENICHIELLO
-
![GettyImages-1480892977-doctor-gene-dna-brain-lungs-heart]( "How Platform Technologies Are Shaping The Gene Therapy Landscape")
How Platform Technologies Are Shaping The Gene Therapy Landscape9/30/2024Leading experts in gene therapy discuss CMC strategy for platform technologies, product lifecycle management, and the role CDMOs play in moving the space forward.
-
![GettyImages-1414998744-scientist-checklist-clipboard-autoclave]( "Gene Therapy CMC Experts On Late-Stage Process Changes")
Gene Therapy CMC Experts On Late-Stage Process Changes9/27/2024At the 2024 Bioprocessing Summit, a panel of CMC experts spoke about the challenges commercializing gene therapies, specifically focusing on considerations for late-stage process changes.
-
![Businessman walks toward goal-GettyImages-1449993219]( "The Future Of Autologous CAR-T Manufacturing: Balancing Innovation With Improvement")
The Future Of Autologous CAR-T Manufacturing: Balancing Innovation With Improvement9/12/2024Experts from last month's Cell & Gene Live event discuss the innovations seen in CAR-T manufacturing and shared their thoughts on the feasibility of decentralized and point-of-care models to address manufacturing challenges.
-
![laptop diary day planner-GettyImages-648963774]( "Key Takeaways From The 2024 Bioprocessing Summit")
Key Takeaways From The 2024 Bioprocessing Summit8/26/2024Editor Tyler Menichiello reflects on the topics and trends covered at this year's Bioprocessing Summit in Boston.
-
![Bioethics-GettyImages-1324565432]( "A Call To Re-Evaluate Islet-Cell Regulations")
A Call To Re-Evaluate Islet-Cell Regulations8/15/2024Autologous islet cell transplantation (AIT) is regulated differently than allogeneic islet cell transplantation, which requires a BLA. Imagine Pharma's Dr. Rita Bottino makes the case for changing these regulations to better serve patients with Type 1 diabetes.
-
![Programming, learning Artificial intelligence isometric robot-GettyImages-2148984216]( "Integrating Analytics And Automation In Cell Therapy Manufacturing")
Integrating Analytics And Automation In Cell Therapy Manufacturing7/31/2024Experts from last month’s Cell & Gene Live event discuss practical ways to utilize emerging technologies.
-
![GettyImages-1388560078-chimeric-antigen-receptor-cell]( "Manufacturing CAR-T In Vivo")
Manufacturing CAR-T In Vivo7/25/2024Manufacturing chimeric antigen receptor (CAR) T-cell therapies is a costly and complicated process. Interius BioTherapeutics is on a mission to reduce this complexity and get these therapies to patients faster — by manufacturing CAR T/NK cells in patients' bodies.
-
![GettyImages-1318086693-atom-molecule-dna-helix]( "Rocket Pharma's Modality-Agnostic Approach To Rare Disease")
Rocket Pharma's Modality-Agnostic Approach To Rare Disease7/24/2024Rocket Pharmaceuticals’ president, COO, and head of R&D, Dr. Kinnari Patel, discusses the company’s modality-agnostic approach to treating rare diseases.
-
![adeno-Associated Virus AAV-GettyImages-1086530890]( "Building A Universal AAV For Cancer")
Building A Universal AAV For Cancer6/28/2024"Universal" isn't the first word most people think of when they think about AAVs. But what if there were such a thing? Siren Biotechnology's CEO, Dr. Nicole Paulk, shares the story behind developing the company's universal AAV immuno-gene therapy.
-
![engraving eyeball-GettyImages-1131307229]( "The Rising Tide Of Ophthalmologic Gene Therapies")
The Rising Tide Of Ophthalmologic Gene Therapies6/27/2024There’s an explosion of clinical activity in the gene therapy space for inherited retinal diseases (IRDs). Atsena Therapeutics' CMO, Dr. Kenji Fujita, explains what makes IRDs such appealing gene therapy targets and shares the company’s strategic approach to clinical development.
